Drugs / Autologous CD123CAR-CD28-CD3zeta-EGFRt-expressing T Lymphocytes
Autologous CD123CAR-CD28-CD3zeta-EGFRt-expressing T Lymphocytes
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02159495 | Dec 2015 → Aug 2026 overdue | CD4+/CD56+ hematodermic neoplasm, acute biphenotypic leukemia, adult acute lymphoblastic leukemia | City of Hope Medical Center | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Autologous CD123CAR-CD28-CD3zeta-EGFRt-expressing T Lymphocytes | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02159495 ↗ |
| Action | Deplete | “recognize and kill cancer cells” NCT02159495 ↗ |
| Modality | Cell therapy | “genetically modified T-cells” NCT02159495 ↗ |
| Route | Intravenous | “Given IV” NCT02159495 ↗ |